Abstract
Introduction: Statins are one of the most widely used therapies in different groups of patients not only because of cholesterol-lowering properties but also due to their non-lipid related mechanisms. However, the effects of atorvastatin on inflammatory and coagulation markers in type 2 diabetic patients are not well examined. Objectives: To evaluate, the effects of two different doses of atorvastatin on lipid profile, inflammatory coagulation markers, and liver enzymes in type 2 diabetic patients. Patients and Methods: In a randomized double-blinded controlled trial, 150 diabetic patients were randomly assigned to get atorvastatin 10 mg/d (n = 74) or 40 mg/d (n = 76) for 12 weeks. The concentration of biomarkers was determined both at the onset of the study as well as at the completing time of the intervention. Results: Significant differences between the mean levels of lipid profiles, fibrinogen, interleukin-1 (IL-1) and IL-6 were observed between two groups after three months treatment with atorvastatin 10 and 40 mg/d (P<0.05). Furthermore, significant improvement in all blood values after atorvastatin 40 mg/d ingestion was observed (P<0.05) except for homocysteine and creatine phosphokinase (CPK) levels (P>0.05). Conclusion: Atorvastatin therapy especially with higher dose was associated with inflammation and coagulation parameters improvement in diabetic individuals.
Highlights
Statins are one of the most widely used therapies in different groups of patients because of cholesterol-lowering properties and due to their non-lipid related mechanisms
Based on independent samples t test (Table 3), significant differences between the mean levels of total cholesterol, low density lipoprotein-cholesterol (LDL-C), HDL-C, fibrinogen, IL-1 and IL-6 were observed between the groups (P < 0.05) while the reduction in the levels of mentioned parameters in group B was greater than group A
Improvement in the serum fasting blood sugar (FBS), HbA1C, AST, TG, total cholesterol, LDL-C, IL-1 and IL-6 values was achieved after treatment with atorvastatin 10 in group A according to paired t test results while, the difference was statistically significant in those markers before and after treatment (P < 0.05)
Summary
Statins are one of the most widely used therapies in different groups of patients because of cholesterol-lowering properties and due to their non-lipid related mechanisms. Objectives: To evaluate, the effects of two different doses of atorvastatin on lipid profile, inflammatory coagulation markers, and liver enzymes in type 2 diabetic patients. Results: Significant differences between the mean levels of lipid profiles, fibrinogen, interleukin-1 (IL-1) and IL-6 were observed between two groups after three months treatment with atorvastatin 10 and 40 mg/d (P < 0.05). Type 2 diabetes mellitus as chronic metabolic disorder, is characterized by inappropriate hyperglycemia due to the deficiency in or resistance to insulin [1]. It has gotten pandemic proportions and regarded as one of the causes of healthcare costs, incapability, and mortality [2]. The effects of different doses of atorvastatin on inflammatory and coagulation markers in type 2 diabetic patients are not well studied
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
